Eric M. Dube Sells 50,691 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) CEO Eric M. Dube sold 50,691 shares of Travere Therapeutics stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $20.21, for a total transaction of $1,024,465.11. Following the completion of the sale, the chief executive officer now directly owns 430,548 shares of the company’s stock, valued at approximately $8,701,375.08. This trade represents a 10.53 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Travere Therapeutics Stock Performance

Shares of TVTX traded up $0.88 during trading hours on Tuesday, hitting $21.10. The company’s stock had a trading volume of 987,233 shares, compared to its average volume of 1,250,242. The business has a 50 day simple moving average of $18.69 and a two-hundred day simple moving average of $15.47. Travere Therapeutics, Inc. has a 52-week low of $5.12 and a 52-week high of $21.56. The company has a debt-to-equity ratio of 24.96, a current ratio of 1.71 and a quick ratio of 1.68. The company has a market cap of $1.65 billion, a price-to-earnings ratio of -4.64 and a beta of 0.72.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Sei Investments Co. bought a new position in shares of Travere Therapeutics in the second quarter worth $117,000. Bank of Montreal Can purchased a new stake in Travere Therapeutics during the 2nd quarter worth about $625,000. AQR Capital Management LLC boosted its stake in Travere Therapeutics by 55.7% in the 2nd quarter. AQR Capital Management LLC now owns 74,069 shares of the company’s stock worth $609,000 after purchasing an additional 26,485 shares during the period. Diversified Trust Co purchased a new position in Travere Therapeutics during the 3rd quarter valued at about $161,000. Finally, CWM LLC grew its holdings in Travere Therapeutics by 158.5% during the 3rd quarter. CWM LLC now owns 4,999 shares of the company’s stock valued at $70,000 after buying an additional 3,065 shares in the last quarter.

Analyst Ratings Changes

A number of analysts recently commented on the company. Piper Sandler boosted their target price on Travere Therapeutics from $12.00 to $22.00 and gave the company a “neutral” rating in a research report on Thursday, November 14th. Barclays boosted their price objective on Travere Therapeutics from $18.00 to $20.00 and gave the company an “overweight” rating in a report on Friday, November 1st. Wells Fargo & Company upgraded shares of Travere Therapeutics from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $9.00 to $27.00 in a report on Monday, October 21st. Wedbush boosted their price objective on Travere Therapeutics from $17.00 to $25.00 and gave the stock an “outperform” rating in a report on Wednesday, October 9th. Finally, HC Wainwright raised their target price on Travere Therapeutics from $18.00 to $22.00 and gave the company a “buy” rating in a report on Wednesday, January 15th. One analyst has rated the stock with a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat, Travere Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $24.00.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.